Eledon Pharmaceuticals
Update in progressELDN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the CD40L pathway to protect transplanted organs, prevent rejection, and treat ALS. Its lead candidate, tegoprubart, is an IgG1 anti-CD40L antibody with high affinity. It targets kidney allograft rejection and xenotransplantation programs and develops NCEL-101 for Type 1 diabetes with NewcelX. Formerly Novus Therapeutics; based in Irvine, California.
Company score
- Sentiment
- 0.16
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.25
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!